PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma
PD-L1 expressed on tumor cells contributes to disease progression with evasion from tumor immunity. Plasma cells from multiple myeloma (MM) patients expressed higher levels of PD-L1 compared with healthy volunteers and monoclonal gammopathy of undetermined significance (MGUS) patients, and its expre...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/4/924 |
| _version_ | 1797571055392391168 |
|---|---|
| author | Hideto Tamura Mariko Ishibashi Mika Sunakawa-Kii Koiti Inokuchi |
| author_facet | Hideto Tamura Mariko Ishibashi Mika Sunakawa-Kii Koiti Inokuchi |
| author_sort | Hideto Tamura |
| collection | DOAJ |
| description | PD-L1 expressed on tumor cells contributes to disease progression with evasion from tumor immunity. Plasma cells from multiple myeloma (MM) patients expressed higher levels of PD-L1 compared with healthy volunteers and monoclonal gammopathy of undetermined significance (MGUS) patients, and its expression is significantly upregulated in relapsed/refractory patients. Furthermore, high PD-L1 expression is induced by the myeloma microenvironment and PD-L1<sup>+</sup> patients with MGUS and asymptomatic MM tend to show disease progression. PD-L1 expression on myeloma cells was associated with more proliferative potential and resistance to antimyeloma agents because of activation of the Akt pathway through PD-1-bound PD-L1 in MM cells. Those data suggest that PD-L1 plays a crucial role in the disease progression of MM. |
| first_indexed | 2024-03-10T20:34:09Z |
| format | Article |
| id | doaj.art-accf204b8f5741eb8fa776fa0231d282 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T20:34:09Z |
| publishDate | 2020-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-accf204b8f5741eb8fa776fa0231d2822023-11-19T21:11:47ZengMDPI AGCancers2072-66942020-04-0112492410.3390/cancers12040924PD-L1–PD-1 Pathway in the Pathophysiology of Multiple MyelomaHideto Tamura0Mariko Ishibashi1Mika Sunakawa-Kii2Koiti Inokuchi3Division of Diabetes, Endocrinology and Hematology, Department of Internal Medicine, Dokkyo Medical University Saitama Medical Center, Saitama 343-8555, JapanDepartment of Microbiology and Immunology, Nippon Medical School, Tokyo 113-8603, JapanDepartment of Hematology, Nippon Medical School, Tokyo 113-8603, JapanDepartment of Hematology, Nippon Medical School, Tokyo 113-8603, JapanPD-L1 expressed on tumor cells contributes to disease progression with evasion from tumor immunity. Plasma cells from multiple myeloma (MM) patients expressed higher levels of PD-L1 compared with healthy volunteers and monoclonal gammopathy of undetermined significance (MGUS) patients, and its expression is significantly upregulated in relapsed/refractory patients. Furthermore, high PD-L1 expression is induced by the myeloma microenvironment and PD-L1<sup>+</sup> patients with MGUS and asymptomatic MM tend to show disease progression. PD-L1 expression on myeloma cells was associated with more proliferative potential and resistance to antimyeloma agents because of activation of the Akt pathway through PD-1-bound PD-L1 in MM cells. Those data suggest that PD-L1 plays a crucial role in the disease progression of MM.https://www.mdpi.com/2072-6694/12/4/924PD-L1 (B7-H1)PD-1multiple myelomamonoclonal gammopathy of undetermined significance (MGUS)immune checkpoint inhibitorsAKT pathway |
| spellingShingle | Hideto Tamura Mariko Ishibashi Mika Sunakawa-Kii Koiti Inokuchi PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma Cancers PD-L1 (B7-H1) PD-1 multiple myeloma monoclonal gammopathy of undetermined significance (MGUS) immune checkpoint inhibitors AKT pathway |
| title | PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma |
| title_full | PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma |
| title_fullStr | PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma |
| title_full_unstemmed | PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma |
| title_short | PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma |
| title_sort | pd l1 pd 1 pathway in the pathophysiology of multiple myeloma |
| topic | PD-L1 (B7-H1) PD-1 multiple myeloma monoclonal gammopathy of undetermined significance (MGUS) immune checkpoint inhibitors AKT pathway |
| url | https://www.mdpi.com/2072-6694/12/4/924 |
| work_keys_str_mv | AT hidetotamura pdl1pd1pathwayinthepathophysiologyofmultiplemyeloma AT marikoishibashi pdl1pd1pathwayinthepathophysiologyofmultiplemyeloma AT mikasunakawakii pdl1pd1pathwayinthepathophysiologyofmultiplemyeloma AT koitiinokuchi pdl1pd1pathwayinthepathophysiologyofmultiplemyeloma |